ZA200504055B - Sinomenine and sinomenine compounds, synthesis and use - Google Patents
Sinomenine and sinomenine compounds, synthesis and use Download PDFInfo
- Publication number
- ZA200504055B ZA200504055B ZA200504055A ZA200504055A ZA200504055B ZA 200504055 B ZA200504055 B ZA 200504055B ZA 200504055 A ZA200504055 A ZA 200504055A ZA 200504055 A ZA200504055 A ZA 200504055A ZA 200504055 B ZA200504055 B ZA 200504055B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compounds
- disease
- dimethoxy
- methyl
- Prior art date
Links
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 title claims description 24
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 title claims description 15
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 title claims description 15
- 229930002966 sinomenine Natural products 0.000 title claims description 15
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 122
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- 230000032683 aging Effects 0.000 claims description 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000002490 cerebral effect Effects 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 10
- 210000001652 frontal lobe Anatomy 0.000 claims description 10
- 230000002739 subcortical effect Effects 0.000 claims description 10
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 230000015654 memory Effects 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- -1 halogen anion Chemical class 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000002140 halogenating effect Effects 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- PHKNOXCRUVPZOB-XAEJFWIOSA-N chembl3302364 Chemical compound C1C(=O)C(OC)=C[C@H]2[C@]3([H])N(C)CC[C@@]21C1=C(O)C(OC)=CC(Br)=C1C3 PHKNOXCRUVPZOB-XAEJFWIOSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 241001387976 Pera Species 0.000 claims 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
- 229960002646 scopolamine Drugs 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 3
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UWEHVAXMSWXKRW-UHFFFAOYSA-N Sinactine Chemical compound C1C2=C3OCOC3=CC=C2CC2N1CCC1=C2C=C(OC)C(OC)=C1 UWEHVAXMSWXKRW-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- KUECBJOPWMRHEX-CQSZACIVSA-N Tuduranine Chemical compound C1C2=CC=C(O)C=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1NCC3 KUECBJOPWMRHEX-CQSZACIVSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003496 anti-amnesic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ALFVETOFBDLGLQ-MRXNPFEDSA-N (+)-Sinactine Natural products O(C)c1c(OC)cc2c([C@@H]3[N+](Cc4c5OCOc5ccc4C3)CC2)c1 ALFVETOFBDLGLQ-MRXNPFEDSA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AXVVWZONCVUAPP-QULPKBGFSA-N Disinomenine Chemical compound C([C@@H]1[C@@H](N(CC2)C)C3)=C(OC)C(=O)C[C@]21C1=C3C(C2=C3C[C@H]4[C@H]5C=C(C(C[C@@]5(CCN4C)C3=C(O)C(OC)=C2)=O)OC)=CC(OC)=C1O AXVVWZONCVUAPP-QULPKBGFSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100291013 Mus musculus Met gene Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KUECBJOPWMRHEX-UHFFFAOYSA-N Tuduranine Natural products C1C2=CC=C(O)C=C2C2=C(OC)C(OC)=CC3=C2C1NCC3 KUECBJOPWMRHEX-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- GQTWBRFNZHWIEF-WDYWJOCVSA-N disinomenine Natural products COC1=C[C@@H]2[C@@H]3Cc4c(c(OC)cc(O)c4[C@]2(CCN3C)CC1=O)c5c6C[C@H]7[C@H]8C=C(OC)C(=O)C[C@@]8(CCN7C)c6c(O)cc5OC GQTWBRFNZHWIEF-WDYWJOCVSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000037043 mnemocognition Effects 0.000 description 1
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 description 1
- 229950004663 nefiracetam Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- GVTRUVGBZQJVTF-YJYMSZOUSA-N salutaridine Chemical compound C1C2=CC=C(OC)C(O)=C2[C@]23C=C(OC)C(=O)C=C3[C@@H]1N(C)CC2 GVTRUVGBZQJVTF-YJYMSZOUSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021538190A CN1328280C (zh) | 2002-11-28 | 2002-11-28 | 汉防己碱和汉防己碱化合物,合成和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504055B true ZA200504055B (en) | 2006-08-30 |
Family
ID=32331921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504055A ZA200504055B (en) | 2002-11-28 | 2005-05-19 | Sinomenine and sinomenine compounds, synthesis and use |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060009480A1 (fr) |
| EP (1) | EP1565444A1 (fr) |
| JP (1) | JP2006509755A (fr) |
| KR (1) | KR100706462B1 (fr) |
| CN (2) | CN1328280C (fr) |
| AU (1) | AU2003290119A1 (fr) |
| BR (1) | BR0316609A (fr) |
| CA (1) | CA2507067A1 (fr) |
| EA (1) | EA200500862A1 (fr) |
| MA (1) | MA27573A1 (fr) |
| MX (1) | MXPA05005687A (fr) |
| NO (1) | NO20053139L (fr) |
| PL (1) | PL377695A1 (fr) |
| WO (1) | WO2004048340A1 (fr) |
| ZA (1) | ZA200504055B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298720C (zh) * | 2005-03-18 | 2007-02-07 | 中国科学院上海有机化学研究所 | C环连接有五元杂环的青藤碱衍生物和合成方法 |
| CN1298718C (zh) * | 2005-03-18 | 2007-02-07 | 中国科学院上海有机化学研究所 | C环连接有吡嗪环的青藤碱衍生物、合成方法及其用途 |
| CN100455571C (zh) * | 2005-12-09 | 2009-01-28 | 湖南正清制药集团股份有限公司 | 青藤碱盐化合物及其制备方法 |
| CN100408578C (zh) * | 2006-03-15 | 2008-08-06 | 南京大学 | 一类17-酰基青藤碱衍生物及其制备方法 |
| WO2007070703A2 (fr) * | 2005-12-15 | 2007-06-21 | Naturemed Group Corporation | Derives de sinomenine et preparation et applications de ceux-ci |
| CN101578101B (zh) * | 2005-12-15 | 2012-05-23 | 自然医学公司 | 青藤碱衍生物的制备和应用 |
| CN101092397B (zh) * | 2006-06-19 | 2011-01-19 | 湖南正清制药集团股份有限公司 | 一种青藤碱结构改造化合物及其制备方法 |
| CN1876634A (zh) * | 2006-06-19 | 2006-12-13 | 湖南正清制药集团股份有限公司 | 一种青藤碱结构改造化合物及其制备方法 |
| US20070290378A1 (en) * | 2006-06-20 | 2007-12-20 | International Business Machines Corporation | Novel reworkable underfills for ceramic mcm c4 protection |
| CN100396686C (zh) * | 2006-08-03 | 2008-06-25 | 西安皓天生物工程技术有限责任公司 | 一种汉防己甲素和汉防己乙素的制备方法 |
| CN102093373A (zh) * | 2007-06-19 | 2011-06-15 | 湖南正清制药集团股份有限公司 | 一种青藤碱结构改造化合物及其制备方法 |
| EP2222643B1 (fr) * | 2007-12-17 | 2019-03-20 | SpecGx LLC | Dérivés de sinoménine et procédés de synthèse |
| CN102325777B (zh) * | 2009-02-23 | 2015-08-12 | 马林克罗特公司 | (+)-吗啡喃*n-氧化物及其制备方法 |
| EP2340832A1 (fr) * | 2009-12-23 | 2011-07-06 | Universität Innsbruck | Composés de morphine-6-one pour le traitement ou la prévention des maladies neurodégénératives |
| CN101798285B (zh) * | 2010-02-10 | 2012-05-23 | 中国科学院上海有机化学研究所 | 一种青藤碱衍生物、合成方法及其用途 |
| CN101899004A (zh) * | 2010-06-24 | 2010-12-01 | 江苏大学 | 青藤碱衍生物、制备方法及其医药用途 |
| CN101948430A (zh) * | 2010-09-01 | 2011-01-19 | 南京大学 | 青藤碱衍生物及其制备方法和应用 |
| CN102532024B (zh) * | 2011-12-28 | 2016-08-03 | 赵爱国 | 青藤碱衍生物 |
| CN104274817B (zh) * | 2014-09-25 | 2016-06-15 | 中山大学 | Wrw三肽在制备治疗阿尔茨海默症药物中的用途 |
| CN104306954B (zh) * | 2014-09-25 | 2016-08-24 | 中山大学 | Wry三肽在制备治疗阿尔茨海默症药物中的用途 |
| CN104258371B (zh) * | 2014-09-25 | 2016-06-15 | 中山大学 | Www三肽在制备治疗阿尔茨海默症药物中的用途 |
| CN104258372B (zh) * | 2014-09-25 | 2017-01-25 | 中山大学 | Rgd三肽在制备治疗阿尔茨海默症药物中的用途 |
| JP7321490B2 (ja) | 2016-02-10 | 2023-08-07 | グレー ピラー ジェームズ | 強化された膨張可能な音波減衰システム |
| CN107648179A (zh) * | 2017-09-21 | 2018-02-02 | 浙江中医药大学 | 一种治疗类风湿性关节炎的新型皮肤给药制剂及其制备方法 |
| CN108704640B (zh) * | 2018-06-13 | 2021-03-30 | 绍兴市梓昂新材料有限公司 | 一种多孔氧化铂催化剂的制备方法 |
| CN110433132B (zh) * | 2019-08-19 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 治疗创伤后应激障碍的粉防己碱鼻用制剂 |
| CN113880764B (zh) * | 2020-07-01 | 2023-04-18 | 北京师范大学 | 青藤碱衍生物及其制备方法与应用 |
| CN114831990A (zh) * | 2022-03-22 | 2022-08-02 | 台州恩泽医疗中心(集团) | 青藤碱在制备治疗帕金森病药物组合物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912114A (en) * | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
| JP3948026B2 (ja) * | 1993-07-19 | 2007-07-25 | 東レ株式会社 | 脳細胞保護剤 |
| JP2002503693A (ja) * | 1998-02-20 | 2002-02-05 | アブマックス，インコーポレイティド | エピモルフィン型化合物及びその使用 |
-
2002
- 2002-11-28 CN CNB021538190A patent/CN1328280C/zh not_active Expired - Fee Related
-
2003
- 2003-11-26 US US10/536,613 patent/US20060009480A1/en not_active Abandoned
- 2003-11-26 JP JP2004554526A patent/JP2006509755A/ja active Pending
- 2003-11-26 AU AU2003290119A patent/AU2003290119A1/en not_active Abandoned
- 2003-11-26 CN CNA200380104606XA patent/CN1720232A/zh active Pending
- 2003-11-26 EP EP03782481A patent/EP1565444A1/fr not_active Withdrawn
- 2003-11-26 PL PL377695A patent/PL377695A1/pl unknown
- 2003-11-26 KR KR1020057009584A patent/KR100706462B1/ko not_active IP Right Cessation
- 2003-11-26 CA CA002507067A patent/CA2507067A1/fr not_active Abandoned
- 2003-11-26 WO PCT/EP2003/014841 patent/WO2004048340A1/fr active Application Filing
- 2003-11-26 BR BR0316609-0A patent/BR0316609A/pt not_active IP Right Cessation
- 2003-11-26 MX MXPA05005687A patent/MXPA05005687A/es not_active Application Discontinuation
- 2003-11-26 EA EA200500862A patent/EA200500862A1/ru unknown
-
2005
- 2005-05-19 ZA ZA200504055A patent/ZA200504055B/en unknown
- 2005-06-27 MA MA28362A patent/MA27573A1/fr unknown
- 2005-06-27 NO NO20053139A patent/NO20053139L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0316609A (pt) | 2005-10-11 |
| MXPA05005687A (es) | 2005-08-16 |
| AU2003290119A1 (en) | 2004-06-18 |
| JP2006509755A (ja) | 2006-03-23 |
| US20060009480A1 (en) | 2006-01-12 |
| CN1328280C (zh) | 2007-07-25 |
| CA2507067A1 (fr) | 2004-06-10 |
| CN1504469A (zh) | 2004-06-16 |
| MA27573A1 (fr) | 2005-10-03 |
| KR100706462B1 (ko) | 2007-04-10 |
| WO2004048340A8 (fr) | 2005-07-07 |
| EP1565444A1 (fr) | 2005-08-24 |
| EA200500862A1 (ru) | 2005-12-29 |
| KR20050071712A (ko) | 2005-07-07 |
| PL377695A1 (pl) | 2006-02-06 |
| WO2004048340A1 (fr) | 2004-06-10 |
| CN1720232A (zh) | 2006-01-11 |
| NO20053139L (no) | 2005-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200504055B (en) | Sinomenine and sinomenine compounds, synthesis and use | |
| Janin et al. | Synthesis and evaluation of new 6-amino-substituted benzo [c] phenanthridine derivatives | |
| EP0030254B1 (fr) | Dérivés de l'acide bêta-carboline-3-carboxylique, compositions pharmaceutiques les contenant et leur utilisation thérapeutique | |
| US5354758A (en) | Benzomorphans useful as NMDA receptor antagonists | |
| US3072530A (en) | Therapeutic indoles for psychic stimulation and relief of mental depression | |
| HU216787B (hu) | Eljárás excitátoros aminosav-antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására | |
| WO2005089294A2 (fr) | Synthese d'indenoisoquinoliniums et techniques d'utilisation | |
| HU185133B (en) | Process for producing 1-hydroxy-octahydro-benzo-bracket-c-bracket closed-quinolines and derivatives | |
| JPH0311067A (ja) | 興奮性アミノ酸拮抗剤 | |
| BG64418B1 (bg) | Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства | |
| DE2839279A1 (de) | Derivate des 1,2,3,3a,8,8a-hexahydropyrrolo eckige klammer auf 2,3-b eckige klammer zu indols, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
| EP0028717A1 (fr) | Dérivés de 6,7-benzomorphane, procédés pour leur préparation, compositions pharmaceutiques contenant lesdits dérivés et leur utilisation comme médicaments | |
| US3629265A (en) | 7-halo-4-isoquinolones | |
| IE45901B1 (en) | Cis-4a-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-2-pyrindines and pharmaceutical compositions containing them | |
| EP0972767A1 (fr) | DERIVES DE CYCLOALCA[b]PYRIDINE-3-CARBONYLGUANIDINE, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS LES CONTENANT | |
| US5330983A (en) | 14-O-p-chlorobenzoylaconine and analgesic/anti-inflammatory agent containing the same | |
| DE3300522A1 (de) | 3,3-dialkyl- und 3,3-alkylen-indolinderivate, verfahren zu ihrer herstellung und pharmazeutische praeparate sie enthaltend | |
| MXPA05000076A (es) | Acutumina y compuestos de acutumina, sintesis y uso. | |
| US4522946A (en) | Dioxy hexahydrobenzo[6,7]cyclohepta[1,2,3-de]isoquinoline derivatives useful as neuroleptic agents | |
| SU1189349A3 (ru) | Способ получени 6-замещенных гексагидроиндазолизохинолинов или их солей | |
| US4304772A (en) | Ethanocarbazole derivatives and antidepressant compositions | |
| CA1108145A (fr) | Derives de benzo¬4,5| cylohepta ¬1,2,3-de| pyrido ¬2,1-a| - isoquinoline, legers tranquilisants | |
| HU215593B (hu) | Izopropil-(2-metoxi-etil)-4-(2-klór-3-ciano-fenil)-1,4-dihidro-2,6-dimetil-piridin-3,5-dikarboxilát, eljárás előállítására és ezt tartalmazó gyógyszerkészítmény | |
| CH638210A5 (fr) | Ester derive de l'acide quinolopyranne-4-one-2-carboxylique, procede de sa preparation et utilisation de cet ester comme compose actif dans un medicament antiallergique pour le traitement de l'asthme. | |
| HU191548B (en) | Process for the production of 1-cyclohexyl-3,4-dihydro-iziquinoline-derivatives |